EBMT 2016

3:06
Defibrotide: Redefining the treatment for severe veno-occlusive disease (sVOD)
Paul Richardson
3:01
Mohamad Mohty on EBMT 2016
Mohamad Mohty
1:09
Blinatumomab for treating ALL
Giovanni Martinelli
2:14
Monoclonal antibodies for difficult-to-treat multiple myeloma
Mohamad Mohty
4:12
Transforming healthcare with Twitter: A physician’s perspective
Navneet Majhail
3:12
Graft-versus-host disease (GvHD): Advances at EBMT 2016
Mohamad Mohty
1:58
New monoclonal antibodies for ALL treatment
Arnon Nagler
3:28
Engaging healthcare professionals and patients with social media
Michael Thompson
1:53
Change of landscape in CLL treatment
John Gribben
1:48
Strategies to reduce graft-versus-host disease (GvHD)
Miguel Perales
4:24
Key questions in the field of CD19 CAR T-cell therapy
Catherine Bollard
1:46
Separation of graft-versus-leukemia from graft-versus-host disease (GvHD)
Arnon Nagler
2:28
The changing role of nurses in bone marrow biopsies
John Murray
1:49
Overview of Phase III clinical trial UKALL14 for ALL
David Marks
1:04
Predicting and diagnosing TB and CMV in hematopoietic cell transplant recipients
Roy Chemaly
1:47
Improving the assessment of response in relapsed MM
Bruno Paiva
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals